Warning letter
Kelley-Ross & Associates, Inc. dba Kelley-Ross Compounding Pharmacy: warning letter of Jul 30, 2018
FDA warning letter 560795 · San Francisco District Office
Key facts
| Reference number | 560795 |
|---|---|
| Company | Kelley-Ross & Associates, Inc. dba Kelley-Ross Compounding Pharmacy |
| Subject | Compounding Pharmacy/Adulterated Drug Products |
| Issue date | Jul 30, 2018 |
| Posted date | Aug 28, 2018 |
| Issuing office | San Francisco District Office |
| Product type | Drugs |
| CFR sections cited | 211.165(a), 210.1(b), 200.10(b), 211.166(a) |
| Inspection city | Seattle |
| Inspection ZIP | 98104 |
| Inspection start date | Jul 17, 2017 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: